This publication is about entering into non-exclusive discount contracts according to § 130a Abs. 8 SGB V for finished medicines containing the active ingredient Abaloparatide (ATC: H05AA04) as part of an "open-house model". Under uniform contract conditions and a standardized access procedure, all
435 days left to bid. Opened 9 months ago, deadline 30 Oct 2027.
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
This contract involves the delivery of natural gas, including network usage, to the buyer's facilities starting from January 1, 2026, at 6:00 AM. Suppliers are invited to provide proposals for the supply of natural gas to AOK Sachsen-Anhalt. The deadline for submissions is July 22, 2025. For more de
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
UKHSA seeks supplier information for Doxycycline 10-pack supply through a preliminary market engagement exercise under the Procurement Act 2023.
Suppliers are invited to complete a preliminary market engagement questionnaire about patient diagnostic and monitoring electrodes by 21st September 2026 through eTendersNI.
